Crystagen
Khavinson-family immune tripeptide with almost no indexed literature.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Crystagen
Crystagen belongs to the family of short peptide bioregulators developed by Khavinson and colleagues from the 1970s onward, the same tradition as the fifteen bioregulators already in this catalog. Vendor documentation gives it as the tripeptide Glu-Asp-Pro (EDP), with a molecular weight of 359.3 — internally consistent with that sequence — and positions it as an immune bioregulator. The honest assessment is that a literature search on 2026-08-04 found no indexed peer-reviewed study of Crystagen specifically. Related peptides from the same family have been studied: Vilon (Lys-Glu), Thymogen (Glu-Trp), Thymalin and Chonluten were evaluated together for effects on inflammatory and proliferative processes in a monocyte/macrophage cell line, and the family's proposed mechanism involves short peptides binding histones and influencing gene expression. That work provides context for the class but is not evidence about this compound. Treat family-level claims as untested here.
Key Benefits
- Part of a long-standing family of short peptide bioregulators
- Proposed epigenetic mechanism shared across the family
- Simple, well-defined tripeptide structure
Set a goal (top of the page) to see how Crystagen scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Not characterised — no indexed study of this compound exists
- Injection site reactions
Legal & Regulatory Status
Research use only. Not FDA-approved. No indexed peer-reviewed study of Crystagen specifically was located; claims rest on family-level reasoning.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- Peptides regulating proliferative and inflammatory pathways in THP-1 monocytes — FAMILY context (Vilon, Thymogen, Thymalin, Chonluten), not Crystagen (PMC8999041)
- Application of peptide bioregulators in gerontology — family review (PMID 11019535)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of August 2026 (8 days ago)
- 10mg $37.9820mg $58.69
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.